Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
• Patient is 14 years or older.
• Diagnosed NF1, determined by American Academy of Neurology Guidelines (see Diagnosis section).
• Tumor Location: cutaneous, trunk, or limbs only.
• Tumor Type: superficial dermal neurofibromas ≤4mm deep.
• Patient has provided written informed consent.
• Patient is willing to and can comply with study follow-up requirements.
• Absence of any other malignancy.